Igenesis

iGenesisBio (奥然生物) develops fully automated nucleic acid detection and analysis systems. The company's Galaxy system, comprising the iCassette smart box and Galaxy series instruments, intelligently completes the full process from sample nucleic acid extraction and purification through fluorescence PCR amplification and analysis in an integrated, fully closed system. iGenesisBio offers instruments including Galaxy Nano, Galaxy Lite, and Universal Pro with varying sample throughputs, along with detection reagents for intestinal diseases, sexually transmitted diseases, respiratory diseases, and vector-borne infectious diseases. The company provides solutions for hospitals, disease control centers, entry-exit inspection and quarantine, and forensic identification, with strong instrument and reagent development and production capabilities. Founded in 2015, headquartered in Shanghai, China, The company has raised $13.0M at the Series C stage, backed by investors including Shenzhen Capital Group, Shenzhen Qianhai Bangqin Investment, Shanghai Kehua Bio-engineering, Morningside, Silicon Harbour Capital..